Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs

Molecular Immunology

Volumn 58, Issue 1, 2014, Pages 132-138

  Mimoto, F ^a   Kadono, S ^a   Katada, H ^a   Igawa, T ^a   Kamikawa, T ^a   Hattori, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

ADCC; Effector function; Fc engineering; Fc R interactions; X ray structure

Indexed keywords

ASYMMETRICAL MONOCLONAL ANTIBODY 23; BLOOD GROUP A ANTIGEN; FC RECEPTOR; FC RECEPTOR IA; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; GEL PERMEATION CHROMATOGRAPHY; HEAVY CHAIN; HINGE REGION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; RECEPTOR BINDING; STATIC ELECTRICITY; SUBSTITUTION REACTION; SURFACE PLASMON RESONANCE; THERMOSTABILITY;

A NOVEL ASYMMETRICALLY ENGINEERED FC; A/I RATIO; ACTIVATING FCΓR BINDING TO INHIBITORY FCΓR BINDING; ADCC; ADCP; ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY; ANTIBODY-DEPENDENT CELL-MEDIATED PHAGOCYTOSIS; ASYM-MAB23; EFFECTOR FUNCTION; FC ENGINEERING; FCΓ RECEPTOR; FCΓR; FCΓR INTERACTIONS; MAB; MONOCLONAL ANTIBODY; PBMC; PDB; PERIPHERAL BLOOD MONONUCLEAR CELLS; PROTEIN DATA BANK; RMS; ROOT-MEAN-SQUARE; SPR; SURFACE PLASMON RESONANCE; X-RAY STRUCTURE;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, IGG; RECOMBINANT PROTEINS;

EID: 84890260986     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.11.017     Document Type: Article

References (25)

1. DeLano W.L. The PyMOL Molecular Graphics System 2002, Schrödinger, LLC, Palo Alto, CA.
2. Emsley P., et al. Features and development of Coot. Acta Crystallogr. 2010, 66D:486-501.
3. Evans P. Scaling and assessment of data quality. Acta Crystallogr. 2006, 62D:72-82.
4. Ferrara C., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12669-12674.
5. Green S.K., et al. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res. 2002, 62:6891-6900.
6. Jung S.T., et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:604-609.
7. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A 1976, 32:922-923.
8. Kabsch W. XDS. Acta Crystallogr. 2010, 66D:125-132.
9. Klein C., et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012, 4:653-663.
10. Krapp S., et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325:979-989.
11. Lazar G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4005-4010.
12. McCoy A.J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
13. Mimoto F., et al. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs 2013, 5:229-236.
14. Murshudov G.N., et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. 2011, 67D:355-367.
15. Oganesyan V., et al. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol. Immunol. 2008, 45:1872-1882.
16. Radaev S., et al. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 2001, 276:16469-16477.
17. Ramsland P.A., et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 2011, 187:3208-3217.
18. Richards J.O., et al. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 2008, 7:2517-2527.
19. Sazinsky S.L., et al. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20167-20172.
20. Scott A.M., et al. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012, 12:14.
21. Shields R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733-26740.
22. Shinkawa T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.
23. Sondermann P., et al. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000, 406:267-273.
24. Stavenhagen J.B., et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007, 67:8882-8890.
25. Winter G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 2010, 43:186-190.